Federal Enforcement Policy Eases Access to Six Unapproved Peptides
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced an enforcement-discretion policy allowing licensed pharmacies and physicians to compound six unapproved peptides. The October policy shift permits the compounding of BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax without FDA enforcement action when specific ingredient, manufacturing, safety-reporting, and labeling requirements are met.
Peptides are short chains of amino acids that serve as the building blocks of proteins and can have a range of effects on the body. While naturally occurring peptides like insulin regulate vital biological processes, wellness markets have increasingly promoted synthetic variants for muscle recovery, anti-aging, and weight loss. Market research firm Grand View Research valued the global peptide industry at over $140 billion in 2025, with North America accounting for more than 60 percent of that revenue.
Medical Experts Warn of Safety Risks Bypassing Clinical Trials
The policy change drew swift criticism from medical associations and regulatory scientists over the lack of rigorous human clinical trials. Willie Underwood III, president of the American Medical Association, stated that allowing pharmacies to compound unapproved synthetic peptides without sufficient evidence of their safety and efficacy puts patients at risk.
Federal regulators previously placed BPC-157 in Category 2 from September 2023 through April 22, 2026, citing potential significant safety risks. Safdar Shabbir Imber Safdar warned that consumers often mistake the enforcement-discretion policy for formal FDA approval, leading them to endanger themselves by taking the peptides.
Regulators and Industry Stakeholders Clash Over Compounding Oversight
An FDA advisory committee convened in July to discuss peptide access, and several panel members had ties to peptide-selling businesses or clinics. FDA staff scientists strongly opposed adding the six compounds to allowable compounding lists, citing insufficient human safety and efficacy data. Public Citizen’s Health Research Group director Robert Steinbrook characterized the unilateral policy action as reckless.
Health Department officials countered that the policy aims to enhance patient choice and offer alternatives to gray-market options. Under the new guidelines, compounding pharmacies must meet requirements on ingredient quality, manufacturing standards, safety reporting, and labeling, though questions remain about the FDA’s ability to enforce these measures.
Frequently Asked Questions About the New Peptide Policy
What specific peptides are covered under the HHS enforcement discretion policy?
The policy covers six unapproved substances: BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax. These compounds are frequently marketed online for uses ranging from tissue repair and insomnia to anti-aging and inflammation.
Did the FDA formally approve these six peptide varieties for human use?
No. The FDA has not approved these substances, and agency scientists opposed their inclusion on compounding lists due to insufficient human safety data. The HHS policy merely pauses enforcement penalties against specialty pharmacies meeting specific manufacturing safeguards.
What requirements must compounding pharmacies meet under the new rules?
Compounding pharmacies and physicians must use peptide ingredients made by registered manufacturers and meet requirements on ingredient quality, manufacturing standards, safety reporting, and labeling.
Background and Implementation of the Compounding Directive
The Department of Health and Human Services announced the loosening of restrictions on six unproven peptides on a Wednesday, following an announcement regarding enforcement discretion.
The agency previously stated there was so little human safety data on BPC-157 that it did not know whether it would cause harm when administered to humans. An FDA advisory committee recommended in July that the agency allow all six peptides in compounding, over the recommendations of FDA staff. The Department of Health and Human Services stated previously that all committee members cleared standard ethics checks.
In January, a Santa Cruz wife and mother of two saw an advertisement for an injectable peptide mix called Glow Stack that included BPC-157.
They’re molecular entities in the body that really tell the cells how to function and what to do in a lot of different ways,
said Krista Capehart, a clinical professor at the WVU School of Pharmacy.